Erratum: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer (The New England Journal of Medicine (2017) 377 (122-131) DOI: 10.1056/NEJMoa1703643);Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer

New England Journal of Medicine

Volumn 377, Issue 2, 2017, Pages 122-131

  Von Minckwitz, Gunter ^a   Procter, Marion ^b   De Azambuja, Evandro ^c   Zardavas, Dimitrios ^d   Benyunes, Mark ^e   Viale, Giuseppe ^d   Suter, Thomas ^f   Arahmani, Amal ^d   Rouchet, Nathalie ^c   Clark, Emma ^e   Knott, Adam ^e   Lang, Istvan ^h   Levy, Christelle ⁱ   Yardley, Denise A ^j   Bines, Jose ^k,n   Gelber, Richard D ^l   Piccart, Martine ^e   Baselga, Jose ^g,m  

^a GBG Forschungs GmbH   (Germany)

^b FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^c Breast European Adjuvant Study Team (BrEAST) Data Center   (Russian Federation)

^d JULES BORDET INSTITUTE   (Belgium)

^e Roche Pharma   (United States)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY OF MILAN   (Italy)

^h NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁱ CENTRE FRANÇOIS BACLESSE   (France)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

^k INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^l HARVARD MEDICAL SCHOOL   (United States)

^m FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; PACLITAXEL; PERTUZUMAB; PLACEBO; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATALITY; FEBRILE NEUTROPENIA; FEMALE; HEART DEATH; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; HEART FAILURE; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIARRHEA; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL RATE; TRASTUZUMAB;

EID: 85023170865     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMx170011     Document Type: Erratum

References (14)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
3. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-83.
4. Zardavas D, Fouad TM, Piccart M. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. Breast 2015; 24: Suppl 2: S143-S148.
5. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-75.
6. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330-6.
7. Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19.
8. Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-34.
9. Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study. Oncologist 2013; 18: 257-64.
10. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
11. Gianni L, Pienkowski T, Im YH, et al. 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or earlystage HER2-positive breast cancer (Neo-Sphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17: 791-800.
12. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
13. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 2007; 25: 2127-32.
14. De Mattos-Arruda L, Shen R, Reis-Filho JS, Cortés J. Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol 2016; 13: 566-79.